Femasys

Atlanta, United States Founded: 2004 • Age: 22 yrs Listed
Medical devices for womens healthcare are developed and provided.

About Femasys

Femasys is a publicly listed company based in Atlanta (United States) founded in 2004. Medical devices for womens healthcare are developed and provided. It operates on a Direct-to-Consumer (D2C) and HealthTech model. Femasys has raised $69.22 million across 18 funding rounds from investors including Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC. The company has 71 employees. Femasys offers products and services including FemaSeed, FemVue, FemBloc, and FemCerv. Its focus areas include Medical Devices and Women's Health Devices. Its legal entity is Femasys Inc. Its competitors include Daré Bioscience, MTM Laboratories and Teal Health; 2 of its 3 listed competitors have raised funding.

Company details

Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.

  • Headquarters Atlanta, United States
  • Employees 71
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website femasys.com
  • Social LinkedIn X Facebook
  • Legal Name Femasys Inc.
Key Metrics
  • Annual Revenue
    $2.29 M (USD)
    40.77
    as on Dec 31, 2025
  • Net Profit
    -$18.63 M (USD)
    1
    as on Dec 31, 2025
  • EBITDA
    -$16.74 M (USD)
    1.04
    as on Dec 31, 2025
  • Total Equity Funding
    $69.22M (USD)

    in 18 rounds

  • Latest Funding Round
    $30M (USD), Post-IPO

    Aug 2026

  • Investors
  • Employee Count
    71

Products & Services of Femasys

Femasys offers a comprehensive portfolio of products and services, including FemaSeed, FemVue, FemBloc, and FemCerv.

FemaSeed
Infertility Treatment

Innovative solution for infertility treatment in women provided.

FemVue
Diagnostic Tool

Diagnostic tool for infertility assessment in women offered.

FemBloc
Birth Control

Permanent birth control solution for women is developed.

FemCerv
Cancer Diagnosis

Tool for cervical cancer diagnosis in women provided.

Funding Insights of Femasys

Femasys has successfully raised a total of $69.22M across 18 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $69.22M
  • Total Rounds 18
  • Last Round Post-IPO — $30M
  • First Round $2.29M

    (Sep 2005)

  • Investors Count 5

Latest 10 of 18 funding rounds of Femasys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2026$30MPost-IPO–Nantahala Capital Management
Nov 2025$8.03MPost-IPO––
–
Jun 2025$1.45MPost-IPO––
–
Nov 2023$6.85MPost-IPO––
Jan 2017$4MSeries C––
–
Dec 2016$40MSeries C–Salem Partners
–
Jul 2016$3.3MSeries B––
–
Jul 2016Debt – Conventional––
–
Apr 2015$10.2MSeries B–Legacy Capital Advisors, LLC
Sep 2013$180,000Series A––
–
Valuation history

5 investors in total: 5 institutional.

Investors in Femasys

Femasys has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Developer of targeted therapeutics for cancer and diabetes
1996pharmacyte.comSilver Spring, United States
Regional investment bank
1997salempartners.comLos Angeles, United States
nantahalapartners.com
rosalindcap.com
yourlegacyteam.net
Premium access

Investor details for Femasys

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Femasys

20 people are tracked at Femasys (9 in leadership, 4 in board & advisors, 7 in team); the tracked headcount is 71.

NameRoleGroup
Amy Beaulieu Rohner
Senior Director, Finance And AdministrationLeadership
Terrell A. Pruitt
VP, ManufacturingLeadership
Dov Elefant
CFOLeadership
Mary An Merchant
VP Counsel, Intellectual PopertyLeadership
Jeremy Sipos
VP, Research & DevelopmentLeadership
Jeffrey Marcus
Chief Medical AdvisorLeadership
Kathy Lee-Sepsick
President, CEO & DirectorLeadership
Valerie Ammons Dawydiak
West Director Of SalesLeadership
Kayla Carlton
Director, Commercial ExcellenceLeadership
Alistair Milnes
Board MemberBoard & advisors
Keith J. Kendall
Board MemberBoard & advisors
Edward Uzialko, Jr.
MemberBoard & advisors
Charles Larsen
MemberBoard & advisors
Christine Thomas
SVP of Regulatory & Clinical AffairsTeam
Richard Spector
Commercial AdvisorTeam
Daniel Currie
SVP, OperationsTeam
Farhan Rahman
Associate Product Development EngineerTeam
Yeisa Whaley
Quality Assurance ManagerTeam
Dongkun H.
Sr. Chemical Development EngineerTeam
Heidi Volk
Human Resources ManagerTeam
Premium access

Complete people profiles for Femasys

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Femasys

Femasys is a publicly listed company on the NASDAQ with ticker symbol FEMY in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jun 2021
  • Listed onNASDAQ: FEMY
  • Listed entityFemasys Inc.
  • Exchange sectorElectronic technology
  • ISINUS31447E2046
  • Share price$1.76 (+0.57% on the day) · 2026-10-13
  • Market capitalisation$14.7M
  • EPS (diluted, trailing year)$-4.62
  • Volume (last session)35,474

Financials of Femasys

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$2.3M-$18.6M-$16.7M
2024$1.6M-$18.8M-$16.9M
2023$1.1M-$14.2M-$13.6M
2022$1.2M-$11.4M-$10.7M
2021$1.2M-$7.5M-$7.4M
Premium access

Detailed financial statements for Femasys

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Femasys

4 dated milestones of Femasys across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Femasys is founded.
  2. Funding First funding round of $2.3M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $30.0M.

Competitors of Femasys

Femasys has 3 listed competitors in our database, 2 of them funded. They include Daré Bioscience, MTM Laboratories and Teal Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
darebioscience.com2005San Diego, United States30
Non-hormonal pharmaceutical products for female contraceptives are developed.
mtm-laboratories.com1999Tucson, United States$76.07M
In vitro diagnostics for early cervical cancer detection are manufactured.
getteal.com2020San Francisco, United States$43.25M6
Cervical cancer screening kits are provided by Teal Health.
Premium access

Detailed competitors of Femasys

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Femasys

The website of Femasys (femasys.com) receives about 9.3K visits a month.

  • Monthly visits
    9.3K

    ▼ 29.3% vs previous month

Top companies in Women's Health & Fertility

3 companies that operate in the same segment as Femasys (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of cell-free DNA testing for oncology, women’s health, and organ health
2004Redwood City, California, United StatesUSD 152.1 MUSD 2.31 B4,430
Therapeutics for women's healthcare are developed and offered.
1997Princeton, New Jersey, United StatesUSD 123.06 MUSD 19.59 M
Provider of cell-free cancer liquid biopsy test
2015San Francisco, California, United StatesUSD 388.62 M861
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Femasys

Premium access

Complete news archive for Femasys

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Femasys

Femasys was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Femasys is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.

Femasys is a funded company, having raised a total of $69.22M across 18 funding rounds to date. The company's 1st funding round was a Series A of $180K, raised on Sep 2005.

Femasys has 71 employees.

Annual revenue of Femasys is $2.29M as on Dec 31, 2025.

Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.

Femasys's top competitors include Daré Bioscience, Teal Health and MTM Laboratories.

Femasys offers FemaSeed, FemVue, FemBloc, and FemCerv.

Yes, Femasys is publicly traded on NASDAQ under the ticker symbol FEMY.

Femasys has 5 investors. Key investors include Salem Partners, PharmaCyte Biotech, Legacy Capital Advisors, LLC, Nantahala Capital Management, and Rosalind Advisors.

Femasys operates through Femasys Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available